PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...

MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve damage develops.

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

NEW YORK--(BUSINESS WIRE)--The Tisch MS Research Center of New York, the world’s largest independent research center focused on multiple sclerosis, has published groundbreaking new research ...

Constipation — having bowel movements less often than usual or stools that are hard or difficult to pass — can affect how you feel throughout your day, disrupt routines, and make other multiple ...

The over‐the‐counter supplement lipoic acid may have a small beneficial effect in slowing the loss of gray matter in the brains of people with progressive forms of multiple sclerosis, according to new ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK inhibitors.

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Clinicians and researchers have suspected for years that an aggressive, less-common form of multiple sclerosis (MS) is likely a distinct form of the disease. Now, new research conducted using a more ...

"Our findings prompt the inevitable question of whether the current phenotype classification of relapse-onset MS into relapsing-remitting and secondary progressive MS is as useful as we thought, for ...

Multiple sclerosis (MS) is best known for the physical symptoms it can cause, such as numbness, weakness, spasticity, and difficulty walking. But this autoimmune disease of the central nervous system ...

Up to 85% of the people who receive a diagnosis of the neurodegenerative disorder multiple sclerosis (MS) have the relapsing-remitting (RR) disease course. This means that people have relapses -- also ...